REGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Regeneron Pharmaceuticals (REGN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite short-term price weakness, the company's strong pipeline, Dupixent growth potential, and hedge fund buying activity make it an attractive long-term investment.
The stock is currently trading at $757.65, slightly below the pivot level of $772.581, with key support at $754.203. The MACD is negatively expanding, indicating bearish momentum, while the RSI at 38.016 is in the neutral zone. Moving averages are converging, suggesting a consolidation phase. Short-term weakness is evident, but the long-term trend remains intact.
Strong sales growth of Dupixent and Eylea HD.
Promising product pipeline with upcoming catalysts like Phase 3 melanoma data and FDA decisions.
Hedge funds significantly increasing their positions in REGN.
Analysts' positive sentiment with multiple price target upgrades, including Barclays' $923 target citing undervaluation.
Short-term headwinds from Eylea and Dupixent LOE uncertainty.
Recent financials show a decline in net income (-7.97% YoY) and EPS (-2.97% YoY).
Current technical indicators suggest bearish momentum in the short term.
In Q4 2025, Regeneron's revenue increased by 2.51% YoY to $3.88 billion, while net income dropped by 7.97% YoY to $844.6 million. EPS declined by 2.97% YoY to $7.84. Gross margin improved slightly to 89.4%, up 1.12% YoY. The financials indicate modest revenue growth but declining profitability.
Analysts are generally bullish on REGN, with multiple price target upgrades. Barclays initiated coverage with an Overweight rating and a $923 price target, citing undervaluation and Dupixent's growth potential. Guggenheim raised its target to $975, highlighting upcoming catalysts. However, some analysts, like RBC and Morgan Stanley, remain cautious due to Eylea headwinds and Dupixent LOE concerns.
